Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

S. Bracarda1, R. Iacovelli2, L. Boni3, M. Rizzo4, L. Derosa5, M. Rossi6, L. Galli5, G. Procopio2, M. Sisani1, F. Longo7, M. Santoni8, F. Morelli9, G. Di Lorenzo10, A. Altavilla7, C. Porta11, A. Camerini12, B. Escudier5, on behalf of the Rainbow Group 1San Donato Hospital USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy 2Tumor National Institute, Milan, Italy 3Clinical Trials Coordinating Center, AOU Careggi, Istituto Toscano Tumori, Florence, Italy 4Medical Oncology; AORN Cardarelli, Napoli, Italy 5Medical Oncology Department, Institut Gustave Roussy, Paris, France 6Medical Oncology, Ospedale Santa Maria della Misericordia, Perugia, Italy 7Medical Oncology, Policlinico Umberto I, Roma, Italy 8Medical Oncology, Polytechnic University of the Marche Region, Ancona, Italy 9Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy 10Genitourinary Cancers Section, AOU Federico II, Napoli, Italy 11Medical Oncology, IRCCS San Matteo, Pavia, Italy 12Medical Oncology, U.O. Oncologia Medica, Ospedale Versilia, Az. USL12, Lido Di Camaiore, Italy Correspondence: sergio.bracarda@usl8.toscana.it Annals of Oncology Advance Access published July 27, 2015